IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases. The ISEE average annual return since 2013 is shown above.
The Average Annual Return on the ISEE average annual return since 2013 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ISEE average annual return since 2013 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ISEE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ISEE Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
